

Disclosure Form Pertaining to ADA Editorial Activities International Committee of Medical Journal Editors (ICMJE) Adapted by the American Diabetes Association

Date: 10/5/2024

Your Name: Ania Jastreboff

Journal Title: Diabetes Care

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to your role as editor for the above-titled journal. “Related” means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The relationships/activities/interests of the editors should be defined broadly. For example, if you are asked to oversee the peer-review of manuscripts pertaining to the epidemiology of diabetes, you should declare all relationships with manufacturers of glucose-lowering medications.

This form was modified by the American Diabetes Association (ADA) in December 2023 to pertain to editorial review activities for ADA professional publications. The original disclosure form developed by the International Committee of Medical Journal Editors (ICMJE) can be found at <https://www.icmje.org/disclosure-of-interest>.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Since the initial planning of the work									
1	Funding support for research projects completed or awarded in the past 36 months (including provision of study materials, article processing charges, etc.)	<input type="checkbox"/> None	<table border="1"> <tr> <td>Global multi-center trials (contracts through institution): Boehringer Ingelheim, Novo Nordisk, Eli Lilly and Company, Rhythm Pharmaceutical, and National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td style="text-align: center;">Click</td> </tr> </table>	Global multi-center trials (contracts through institution): Boehringer Ingelheim, Novo Nordisk, Eli Lilly and Company, Rhythm Pharmaceutical, and National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases					Click
Global multi-center trials (contracts through institution): Boehringer Ingelheim, Novo Nordisk, Eli Lilly and Company, Rhythm Pharmaceutical, and National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases									
	Click								
Continues on the next page									

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)						
Time frame: Past 36 months									
2	Grants or contracts from any entity (if not indicated in item #1 above).	<input type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 10px;"> <tr> <td>National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td style="text-align: center;">Click the tab key to add additional rows.</td> </tr> </table>	National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases					Click the tab key to add additional rows.	
National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases									
	Click the tab key to add additional rows.								
3	Royalties or licenses	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 10px;"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td style="text-align: center;">Click the tab key to add additional rows.</td> </tr> </table>						Click the tab key to add additional rows.	
	Click the tab key to add additional rows.								
4	Consulting fees	<input type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 10px;"> <tr> <td>serves as Scientific Advisor and/or on Scientific Advisory Boards for AstraZeneca, Amgen, Boehringer Ingelheim, Biohaven, Eli Lilly and Company, Intellihealth, Novo Nordisk, Pfizer, Regeneron, Scholar Rock, Structure Therapeutics, Terns Pharmaceuticals, WeightWatchers, and Zealand Pharmaceuticals</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td style="text-align: center;">Click.</td> </tr> </table>	serves as Scientific Advisor and/or on Scientific Advisory Boards for AstraZeneca, Amgen, Boehringer Ingelheim, Biohaven, Eli Lilly and Company, Intellihealth, Novo Nordisk, Pfizer, Regeneron, Scholar Rock, Structure Therapeutics, Terns Pharmaceuticals, WeightWatchers, and Zealand Pharmaceuticals					Click.	
serves as Scientific Advisor and/or on Scientific Advisory Boards for AstraZeneca, Amgen, Boehringer Ingelheim, Biohaven, Eli Lilly and Company, Intellihealth, Novo Nordisk, Pfizer, Regeneron, Scholar Rock, Structure Therapeutics, Terns Pharmaceuticals, WeightWatchers, and Zealand Pharmaceuticals									
	Click.								
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	<input type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 10px;"> <tr> <td>Educational activities: has received honoraria or travel support from Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, and WeightWatchers</td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td style="text-align: center;">Click the tab key to add additional rows.</td> </tr> </table>	Educational activities: has received honoraria or travel support from Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, and WeightWatchers					Click the tab key to add additional rows.	
Educational activities: has received honoraria or travel support from Boehringer Ingelheim, Eli Lilly and Company, Novo Nordisk, and WeightWatchers									
	Click the tab key to add additional rows.								
6	Payment for expert testimony	<input checked="" type="checkbox"/> None <table border="1" style="width: 100%; margin-top: 10px;"> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td></td> </tr> <tr> <td></td> <td style="text-align: center;">Click the tab key to add additional rows.</td> </tr> </table>						Click the tab key to add additional rows.	
	Click the tab key to add additional rows.								

7	Support for attending meetings and/or travel	<input type="checkbox"/> None	
		travel support from Novo Nordisk, Boehringer Ingelheim, Eli Lilly and Company, and WeightWatchers	
		Click the tab key to add additional rows.	

Continues on the next page

8	Patents planned, issued or pending	<input checked="" type="checkbox"/> None	
		Click the tab key to add additional rows.	

9	Participation on a Data Safety Monitoring Board or Advisory Board	<input type="checkbox"/> None	
		University of Minnesota, DSMB for two studies	
		Click the tab key to add additional rows.	

10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	<input type="checkbox"/> None	
		Governance Board The Obesity Society	
		Obesity Algorithm Task Force American Assoc Clin Endo	
		Assoc Editor American Diabetes Association Diabetes Care	Click the tab key to add additional rows.

11	Stock or stock options	<input type="checkbox"/> None	
		Intellihealth	
		Click the tab key to add additional rows.	

12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	<input type="checkbox"/> None	
		Novo Nordisk study medication	
		Click the tab key to add additional rows.	

13	Other financial or non-financial interests	<input checked="" type="checkbox"/> None	
			Click the tab key to add additional rows.

Please place an “X” next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.